IL-17A inhibitor 1 is a IL-17A inhibitor with IC50 of <9.45 nM in alphalisa assay. IL-17A inhibitor 1 inhibits HT-29 cells with IC50 of 9.3 nM.

IL-17A antagonist 3 is an IL-17A antagonist.

IL-17A Modulator-3, an inhibitor of IL-17A/A, exhibits an IC 50 value of less than 10 μM. It is utilized in research related to inflammation, cancer, and autoimmune diseases.

IL-17A modulator-2, exhibits inhibitory properties towards IL-17A, with a pIC50 of 8.3. Its effectiveness lies in attenuating the biological effects associated with IL-17A activity. IL-17A modulator-2 finds utility in the study of diseases and disorders characterized by dysregulated IL-17A modulation, such as those involving immune dysfunction, autoimmune pathology, cancer, and neurodegenerative conditions.

IL-17A antagonist 1 is an IL-17A antagonist for the study of interleukin-related inflammatory and immune diseases.

IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis.

Anti-Human IL-17A is a fully human anti- interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis [1] .

IL-17A modulator-1 is an effective inhibitor of IL-17A activity, exhibiting a pIC 50 value of 8.2. This compound holds great promise for studying diseases and disorders that involve the modulation of IL-17A, such as immune-related diseases, autoimmune pathologies, cancer, and neurodegenerative disorders.

cephalandole B, an indole alkaloid isolated from cyanide, significantly inhibited IL-17A gene expression and suppressed IL-17A luciferase reporter in Jukat cells in a dose-dependent manner.

12R-LOX-IN-2 is an inhibitor of 12R-lipoxygenase (12R-LOX).12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and inhibits colony formation.12R-LOX-IN-2 also decreases the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 may be useful in the study of psoriasis and other skin-associated inflammatory diseases.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

Fulvotomentoside A could decrease overexpression of IL-6 and IL-17A, and increase the expression of specific transcription factor Foxp3 of regulatory T cells significantly in intestine. It may be one of the mechanisms that Ful improved intestinal inflamma

12R-LOX-IN-1 (Compound 4a), with an IC50 of 28.25 µM, is an inhibitor of 12R-LOX. It suppresses the hyperproliferative condition and the ability to form colonies in Imiquimod-induced psoriatic keratinocytes, as well as reducing levels of reactive oxygen species, Ki67, IL-17A, TNF-α, and IL-6. This compound has utility in antipsoriatic research [1].

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, both of which promote osteogenic differentiation in human periosteum-derived cells (hPDC). Consequently, Bimekizumab inhibits inflammation-driven osteogenic differentiation [1].

Xeligekimab (GR 1501) is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) to inhibit the pro-inflammatory cascade [1].

Gumokimab (AK 111), a monoclonal antibody, targets IL-17A and is utilized in researching psoriasis and ankylosing spondylitis. It competitively inhibits the interaction between human IL-17A and its receptor, IL-17R.

ARN-6039 is an orally available inverse agonist of RORγ for Autoimmune Neuroinflammatory Demyelinating Disease. The activity of ARN-6039 against RORγ was demonstrated in a RORγ-activated IL-17A Prom/LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 r

MRL-871 (compound 3) is a potent isotretinoin receptor-related orphan receptor γt (RORγt) inverse agonist (IC50: 264 nM).MRL-871 has a specific isoxazole chemotype and is effective in reducing IL-17a mRNA production in EL4 cells.

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

Remtolumab (ABT-122), a dual-variable domain immunoglobulin, neutralizes tumor necrosis factor α (TNFα) and IL-17A, demonstrating dual inhibition of both. This compound is utilized in rheumatoid arthritis (RA) research [1] [2].

FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells. FM26 is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM.

RORγt Inverse agonist 10 is a highly potent and orally bioavailable compound that acts as an antagonist for the retinoic acid receptor-related orphan nuclear receptor gamma t (RORγt). With an IC50 of 51 nM, it effectively inhibits the activity of RORγt, a prominent transcription factor involved in the regulation of genes associated with the pathogenesis of psoriasis, including IL-17A, IL-22, and IL-23R.

Androgen receptor-IN-5 is a potent inhibitor of the androgen receptor with anticancer properties. It additionally suppresses the synthesis of IL-17A, IL-17F, and INF-γ.

Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

7β,27-dihydroxy Cholesterol is an oxysterol and agonist of retinoic acid receptor-related orphan receptor γ (RORγ) and RORγt. [1] It activates RORγ- or RORγt-dependent signaling with EC50 values of 691 and 1,045 nM, respectively, in reporter assays using HEK293T cells expressing the recombinant human receptors. 7β,27-dihydroxy Cholesterol is selective for RORγ and RORγt over a panel of eight additional nuclear receptors at 30 µM. It increases IL-17A production in Th17-polarized isolated human na ve CD4+ T cells when used at a concentration of 300 nM. 7β,27-dihydroxy Cholesterol (60 mg/kg) increases IL-17A production in isolated mouse γδ T cells stimulated with 12-myristate 13-acetate and ionomycin .

Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist [1] .

STK630921 is a blocker of IL-17A binding to the IL-17A receptor (IL-17RA).

Tibulizumab (LY 3090106), a tetravalent bispecific monoclonal antibody, selectively binds to B-cell activating factor (BAFF) and IL-17A with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This specificity renders it a valuable tool for autoimmune disease research.

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody that combines monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F, along with human serum albumin VHHs. This composition presents sonelokimab as a promising candidate for the investigation of plaque-type psoriasis treatments [1] [2].

AX-024 is a novel chemical compound that acts as an orally available inhibitor of the TCR-Nck interaction. Its primary mechanism of action is the selective inhibition of T cell activation triggered by TCR stimulation. With an IC50 value of approximately 1 nM, AX-024 effectively modulates cell signaling by specifically targeting SH3 domains. Additionally, AX-024 demonstrates desirable characteristics such as low acute toxicity, high potency, and excellent selectivity. Notably, it exhibits strong inhibitory effects on the production of IL-6, TNF-α, IFN-γ, IL-10, and IL-17A.

JNJ-61803534 is a potent, orally active RORγt inverse agonist, demonstrating anti-inflammatory activity through inhibition of IL-17A production in human CD4+ T cells under Th17 differentiation conditions, with an IC50 of 9.6 nM.

RORγt modulator 4 is a RORγt modulator that regulates IL-17A production activity in cells derived from mouse spleen.

A-9758 is a RORγ ligand and a selective RORγt inverse agonist (IC50: 5 nM) and exhibits robust potency against IL-17A release. It is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 drive

Vimirogant (VTP-43742) hydrochloride is an orally active, selective RORγt inhibitor (IC50: 17 nM, Ki: 3.5 nM) that is more than 1000 times more selective than RORα and RORβ. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion in mouse spleen cells with an IC50 value of 57 nM and does not affect the differentiation of Th1, Th2 or Treg cells.

GSK2981278 (ROR gama modulator 1) is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

Afasevikumab (RG 7624; RO 5553110; NI-1401), a fully human monoclonal IgG1κ antibody, neutralizes both IL-17A and IL-17F, exhibiting anti-inflammatory activities [1].

ROR agonist-1 is a potent and orally bioavailable the retinoic acid receptor-related orphan receptor C2 (RORC2) inverse agonist(inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5).

Vunakizumab (Anti-Human IL17A Recombinant Antibody), a recombinant human IgGκ monoclonal antibody, specifically targets and inhibits IL-17A's interaction with its receptor, making it useful for researching autoimmune conditions including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Perakizumab (RG4934), a humanized IgG1κ monoclonal antibody targeting IL-17A (Interleukin Related), is utilized in the study of autoimmune conditions, including psoriatic arthritis [1].

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis.